All In Biotech

Drug Trial Radar · NCT06138743

Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy

A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DM1 (SRP-1003) in Subjects With Type 1 Myotonic Dystrophy Who Are ≥18 to ≤ 65 Years

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

78

Planned (sponsor's estimate)

Start

Mar 4, 2024

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Sarepta Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1/2a double-blinded, placebo-controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of single and multiple ascending doses of SRP-1003 compared to placebo in male and female participants with type 1 myotonic dystrophy (DM1). Participants who have provided written informed consent and met all protocol eligibility requirements will be randomized to receive single (Part 1) or multiple (Part 2) doses of SRP-1003 or placebo.

Conditions

  • Myotonic Dystrophy 1

Interventions

  • SRP-1003 IV InfusionDrug

    SRP-1003 by IV infusion

  • Placebo IV InfusionDrug

    0.9% sodium chloride (NaCl) calculated volume to match active treatment by IV infusion

  • SRP-1003 SC InjectionDrug

    SRP-1003 by SC injection(s)

  • Placebo SC InjectionDrug

    0.9% NaCl calculated volume to match active treatment by SC injection(s)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment-emergent Adverse Events Over Time Through End of Study (EOS)Time frame: Single-dose phase (Part 1): Up to Day 90 (EOS); multiple-dose phase (Part 2): Up to Day 180 (EOS)

Locations

35 sites in 11 countries. Site status is shown where the registry gives one.

  • Nucleus Network Brisbane Clinic

    Herston, Australia

  • Mater Hospital Brisbane

    South Brisbane, Australia

  • Liverpool Hospital

    Liverpool, New South Wales, Australia

  • Sunshine Coast University Hospital

    Birtinya, Queensland, Australia

  • Royal Brisbane And Women's Hospital

    Herston, Queensland, Australia

  • Alfred Health

    Melbourne, Victoria, Australia

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • UZ Leuven

    Leuven, Belgium

  • University Of Calgary

    Calgary, Canada

  • University Of Alberta

    Edmonton, Canada

  • McGill University

    Montreal, Canada

  • University Hospital of Angers

    Angers, France

  • Centre Hospitalier Universitaire De Bordeaux

    Bordeaux, France

  • Centre Hospitalier Universitaire De Lille

    Lille, France

  • CHU de Nice - Hôpital Pasteur 2

    Nice, France

  • Assistance Publique Hôpitaux De Paris

    Paris, France

  • Klinikum der Universität München AöR

    Munich, Germany

  • Deutsches Zentrum für Neurodegenerative Erkrankungen e.V.

    Ulm, Germany

  • Fondazione Serena Onlus - Centro Clinico Nemo Brescia

    Gussago, Italy

  • Centro Clinico Nemo (Milan)

    Milan, Italy

  • Azienda Ospedaliera Universitaria Pisana (AOUP)

    Pisa, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Roma, Italy

  • New Zealand Clinical Research Christchurch

    Christchurch, New Zealand

  • Hospital Universitario Torrecárdenas

    Almería, Spain

  • Hospital Universitari Vall D Hebron

    Barcelona, Spain

  • Hospital Universitario Infanta Sofia

    Madrid, Spain

  • China Medical University Hospital

    Taichung, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • Siriraj Hospital

    Bangkok, Thailand

  • Lampang Hospital

    Lampang, Thailand

  • Songklanagarind Hospital

    Hat Yai, Changwat Songkhla, Thailand

  • The National Hospital for Neurology and Neurosurgery, NHS Foundation Trust

    London, United Kingdom

  • Nottingham University Hospitals NHS Trust

    Nottingham, United Kingdom

  • Southampton General Hospital, NHS Foundation Trust

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.